Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma
Copyright © 2023 Elsevier Inc. All rights reserved..
Chimeric antigen receptor T cells (CARTs) represent another powerful way to leverage the immune system to fight malignancy. Indeed, in multiple myeloma, the high response rate and duration of response to B cell maturation antigen-targeted therapies in later lines of disease has led to 2 Food and Drug Administration (FDA) drug approvals and opened the door to the development of this drug class. This review aims to provide an update on the 2 FDA-approved products, summarize the data for the most promising next-generation multiple myeloma CARTs, and outline current challenges in the field and potential solutions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Hematology/oncology clinics of North America - 38(2024), 2 vom: 06. Apr., Seite 383-406 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hasanali, Zainul S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.03.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.hoc.2023.12.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366488872 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366488872 | ||
| 003 | DE-627 | ||
| 005 | 20240409232317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.hoc.2023.12.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM366488872 | ||
| 035 | |a (NLM)38158242 | ||
| 035 | |a (PII)S0889-8588(23)00171-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hasanali, Zainul S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Chimeric antigen receptor T cells (CARTs) represent another powerful way to leverage the immune system to fight malignancy. Indeed, in multiple myeloma, the high response rate and duration of response to B cell maturation antigen-targeted therapies in later lines of disease has led to 2 Food and Drug Administration (FDA) drug approvals and opened the door to the development of this drug class. This review aims to provide an update on the 2 FDA-approved products, summarize the data for the most promising next-generation multiple myeloma CARTs, and outline current challenges in the field and potential solutions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a B cell maturation antigen (BCMA) | |
| 650 | 4 | |a Chimeric antigen receptor Tcells (CARTs) | |
| 650 | 4 | |a Cytokine release syndrome (CRS) | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a Relapsed/refractory multiple myeloma | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a B-Cell Maturation Antigen |2 NLM | |
| 700 | 1 | |a Razzo, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Susanibar-Adaniya, Sandra P |e verfasserin |4 aut | |
| 700 | 1 | |a Garfall, Alfred L |e verfasserin |4 aut | |
| 700 | 1 | |a Stadtmauer, Edward A |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Adam D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematology/oncology clinics of North America |d 1991 |g 38(2024), 2 vom: 06. Apr., Seite 383-406 |w (DE-627)NLM013047507 |x 1558-1977 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:2 |g day:06 |g month:04 |g pages:383-406 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hoc.2023.12.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 2 |b 06 |c 04 |h 383-406 | ||